ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1500 participants.
Also called NCT05932615
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,500 participants
- Sponsor
- Registry
-
NCT05932615
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, Sweden, Switzerland, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT05932615. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
- Acronym
- ENVISION
- Condition
- Aortic Valve Stenosis
- Condition
- Heart Valve Diseases
- Condition
- Aortic Valve Disease
- Condition
- Heart Disease Structural Disorder
- Intervention (Device)
- Navitor Transcatheter Aortic Valve Implantation (TAVI) System
- Intervention (Device)
- Any Commercially Available Transcatheter Aortic Valve (CAV) System
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct05932615- Content hash
a335f3d3c0e8cf3526710354d6d1234c7975735305bf680bbfda7a7533d32ab5